Loading...
•
Jun 30, 2021
Tarsus Q2 2021 Earnings Report
Tarsus Pharmaceuticals reported positive results from Saturn-1 trial, initiated Saturn-2 and Callisto trials, and announced second quarter 2021 financial results.
Key Takeaways
Tarsus Pharmaceuticals announced positive results from the Saturn-1 pivotal trial for TP-03, initiated the Saturn-2 and Callisto trials, and reported a net income of $6.3 million for the second quarter of 2021, compared to a net loss of $(3.3) million for the same period in 2020.
Announced positive results from the Saturn-1 pivotal trial evaluating TP-03 for Demodex blepharitis.
Initiated Saturn-2, the second pivotal Phase 3 trial evaluating TP-03 for Demodex blepharitis.
Initiated the Phase 1 Callisto trial evaluating TP-05 for the prevention of Lyme disease.
Cash and equivalents of $177 million, plus TP-03 license receivables of $20 million as of June 30, 2021.